Introduction:

Recurrent respiratory papillomatosis (RRP) is a chronic condition associated with the growth of papillomas in the airways, with impaired voice and respiratory quality. Recent studies have shown that intralesional injection of bevacizumab increases the interval between surgeries, improves quality of life, and has a virtually zero risk of complications.

Objectives:

To establish a protocol for intralesional application of bevacizumab in patients with severe RRP.

Materials and Methods:

The search included the PUBMED and Cochrane databases. A review of relevant medical literature was conducted.

Results:

The protocol consists of four distinct phases: selection of patients with severe RRP requiring adjuvant therapy and obtaining informed consent, staging and assessment of preoperative disease burden, implementation of adjuvant treatment with intralesional bevacizumab as outlined, and follow-up and efficacy criteria.

Conclusions:

For the treatment of severe RRP, this standardized technique provides a systematic method for injecting bevacizumab intralesionally.

        · abstract in Portuguese     · text in Portuguese     · Portuguese ( pdf )